# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
-SEC Filing
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $...
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.030) per share which beat the analyst consensus estimate...
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...